Last updated on March 2020

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).


Brief description of study

This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine , oxaliplatin-, and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.

Clinical Study Identifier: NCT03564938

Find a site near you

Start Over